Drug Trial Radar · NCT06241118
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
464
Actual
Start
Feb 29, 2024
Primary completion
Sep 30, 2027
Study completion Sep 29, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
PlaceboDrug
Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Topical corticosteroidsDrug
Pharmaceutical form: Various Topical formulation Route of administration: Topical
Topical tacrolimus or pimecrolimusDrug
Pharmaceutical form: Various Topical formulation Route of administration: Topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36Time frame: Week 36
- EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI75) at Week 36Time frame: Week 36
- US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36Time frame: Week 36
Locations
154 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- Site Number : 8401267
Birmingham, Alabama
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona
Arkansas Dermatology - North Little Rock- Site Number : 8401244
North Little Rock, Arkansas
Exalt Clinical Research- Site Number : 8401344
Chula Vista, California
Encino Research Center- Site Number : 8401042
Encino, California
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California
Long Beach Clinical Trials- Site Number : 8401188
Long Beach, California
Dermatology Research Associates- Site Number : 8401092
Los Angeles, California
LA Universal Research Center- Site Number : 8401064
Los Angeles, California
University Dermatology Trials- Site Number : 8401339
Newport Beach, California
Rady Children's Hospital- Site Number : 8401291
San Diego, California
Therapeutics Clinical Research- Site Number : 8401283
San Diego, California
Paradigm Clinical Research - Wheat Ridge- Site Number : 8401245
Wheat Ridge, Colorado
Encore Medical Research of Boynton Beach- Site Number : 8401030
Boynton Beach, Florida
St. Jude Clinical Research- Site Number : 8401287
Doral, Florida
Apex Clinical Research - Jacksonville- Site Number : 8401332
Jacksonville, Florida
Clever Medical Research- Site Number : 8401160
Miami, Florida
Future Care Solution - Miami- Site Number : 8401340
Miami, Florida
Global Clinical Professionals (GCP)- Site Number : 8401045
St. Petersburg, Florida
Avita Clinical Research- Site Number : 8401073
Tampa, Florida
Northwestern University- Site Number : 8401285
Chicago, Illinois
NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8401038
Skokie, Illinois
Dawes Fretzin Clinical Research- Site Number : 8401015
Indianapolis, Indiana
Equity Medical - Bowling Green- Site Number : 8401296
Bowling Green, Kentucky
Tandem Clinical Research - Metairie- Site Number : 8401187
Metairie, Louisiana
University of Michigan Health System - Ann Arbor- Site Number : 8401290
Ann Arbor, Michigan
MI Skin Center- Site Number : 8401307
Northville, Michigan
Schweiger Dermatology Group - East Windsor- Site Number : 8401338
East Windsor, New Jersey
The University of New Mexico- Site Number : 8401263
Albuquerque, New Mexico
Sadick Research Group - New York - Park Avenue- Site Number : 8401050
New York, New York
Equity Medical (LLC)- Site Number : 8401239
The Bronx, New York
Cincinnati Children's Hospital Medical Center- Site Number : 8401279
Cincinnati, Ohio
Oregon Health & Science University (OHSU)- Site Number : 8401247
Portland, Oregon
Paddington Testing Company- Site Number : 8401041
Philadelphia, Pennsylvania
Clinical Research of Philadelphia- Site Number : 8401193
Philadelphia, Pennsylvania
Medical University of South Carolina - Charleston - Jonathan Lucas Street- Site Number : 8401282
Charleston, South Carolina
Arlington Research Center- Site Number : 8401248
Arlington, Texas
McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8401288
Bellaire, Texas
Reveal Research Institute - Dallas- Site Number : 8401219
Dallas, Texas
Virginia Dermatology & Skin Cancer Center- Site Number : 8401047
Norfolk, Virginia
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.